Apexigen, Inc. (APGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

10.98

-0.48

(-4.19%)

As of 02:03PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Relative Strength Index (RSI)

View all chart patterns

Performance Outlook

Previous Close	11.46
Open	10.28
Bid	11.20 x 800
Ask	11.43 x 900
Day's Range	10.25 - 11.39
52 Week Range	9.50 - 31.35
Volume	137,876
Avg. Volume	59,830

Market Cap	344.723M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for APGN

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Apexigen, Inc.
Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Rating
Fair Value
Economic Moat
5 days agoMorningstar

All

Simply Wall St.
Is Apexigen (NASDAQ:APGN) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
  Simply Wall St.
- Canoo burns cash in race to hit $1B EV sales goal
  TechCrunch
GlobeNewswire
Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference
SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that the Company’s Management will participate virtually in the Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022. 2022 Wedbush PacGrow Healthcare ConferenceFormat: Panel discussion and one-on-one investor meetingsTopic: For Your IOnly -